Peter K. Schulz-Knappe

Nessuna posizione attualmente

62 anni

Health Technology

Commercial Services

Profilo

Peter K.
Schulz-Knappe is the founder of Digilab BioVisioN GmbH, which was founded in 1997.
He held the title of Director-Research from 1997 to 2010.
Currently, he is the Chief Scientific Officer at Protagen AG since 2010.
In the past, he worked as the Director-Research & Development at Proteome Sciences Plc from 2006 to 2009.
He also worked as the Chief Technology Officer at Immunovia AB.

Precedenti posizioni note di Peter K. Schulz-Knappe

Società	Posizione	Fine
IMMUNOVIA AB	Direttore Tecnico/Scientifico/R&S	31/08/2020
PROTEOME SCIENCES PLC	Direttore Tecnico/Scientifico/R&S	31/12/2009
Protagen AG Protagen AG BiotechnologyHealth Technology Protagen AG specializes in the development of novel diagnostic and companion diagnostic tests. Its products and services include GMP analyses, protein identification and analyses, proteome studies, UNIchip, clone and array, Bio-IT, Modiro as well as ProteinScape and Solver. The company was founded by Stefan Müllner, Helmut E. Meyer, Petra Weingarten and Martin Blüggel in 1997 and is headquartered in Dortmund, Germany.	Direttore Tecnico/Scientifico/R&S	-
Digilab BioVisioN GmbH Digilab BioVisioN GmbH Miscellaneous Commercial ServicesCommercial Services Digilab BioVisioN GmbH provides research services in the area of peptide analysis to health care by discovering and developing novel substances and methods to diagnose and treat human diseases. Its partners include Roche Diagnostics GmbH for the discovery of novel biomarker candidates of Alzheimer's disease and Novo Nordisk for the search for novel therapeutic approaches in type 2 diabetes. The company was founded in 1997 and is headquartered in Hannover, Germany.	Fondatore	-

Vedi nel dettaglio l'esperienza di Peter K. Schulz-Knappe

Esperienze
Posizioni ricoperte

Attive

Inattive

Società quotate in Borsa

Aziende private